Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China

Published:2019-03-20 Issue:6 Volume:22 Page:584-592
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Liao Mengting¹,Jiang Qin²,Hu Huabin³,Han Jiaqi¹,She Longjiang¹,Yao Linli¹,Ding Dong¹,Huang Jin¹

Affiliation:

1. Departmen of Oncology, Xiangya Hospital, Central South University, Changsha, PR China;

2. Department of Respiratory, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, PR China;

3. Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China

Funder

Natural Science Foundation of Hunan Province

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1588125

Reference35 articles.

1. Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer

2. Molecular portraits of human breast tumours

3. The Emerging Role of the Molecular Diagnostics Laboratory in Breast Cancer Personalized Medicine

4. Network-based approach to identify prognostic biomarkers for estrogen receptor–positive breast cancer treatment with tamoxifen

5. Repeated observation of breast tumor subtypes in independent gene expression data sets

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis;Oral Oncology;2024-07

2. Cost-effectiveness of Metronomic chemotherapy vs Weekly Intravenous Paclitaxel in patients with ER+/HER2-Metastatic Breast Cancer;2024-01-23

3. Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer;Gynecologic Oncology;2023-07

4. The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis;Cancers;2023-02-12

5. Factors Affecting Health-Related Quality of Life in Patients With Metastatic Breast Cancer;Journal of Breast Cancer;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3